Medical tech firm Biolidics set for SGX Catalist debut

A logo of the Singapore Stock Exchange (SGX) is pictured outside its premises in the financial district of Singapore April 23, 2014. REUTERS/Edgar Su/Files

Singapore-based medical technology Biolidics Limited is tapping the SGX Catalist market by issuing 27.5 million placement shares at S$0.28 apiece to raise approximately S$7.7 million ($5.6 million) in gross proceeds from the IPO.

The IPO offer closes on December 17, 2018, and listing will take place on December 19, 2018. United Overseas Bank (UOB) Limited is managing the issue.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter